Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2018, No. 6


Maldonado-Calderón JL, López-Márquez FC, Ruiz-Flores P
¿Azitromicina como tratamiento contra Chlamydia trachomatis?
Gac Med Mex 2018; 154 (6)

Idioma: Español
Referencias bibliográficas: 29
Paginas: 689-692
Archivo PDF: 158.74 Kb.


Texto completo




RESUMEN

Se ha demostrado la efectividad de la azitromicina y la doxiciclina en el tratamiento de la clamidiasis urogenital, lo que se ha mantenido sin cambios por mucho tiempo. Se ha propuesto la autoinoculación como método de reinfección y persistencia de la enfermedad en las mujeres y también debido a la farmacocinética de la azitromicina en este tejido. Con los nuevos métodos diagnósticos y las pruebas de curación se ha comprobado una diferencia a favor de la doxiciclina en el tratamiento de la clamidiasis rectal. La resistencia antimicrobiana no ha desempeñado un papel relevante porque no se han encontrado cepas resistentes in vivo al tratamiento. A pesar de ello, la azitromicina sigue siendo un fármaco de primera elección ya que puede administrarse como una dosis única, lo que favorece el apego terapéutico.


Palabras clave: Chlamydia trachomatis, Azitromicina, Prueba de curación.


REFERENCIAS

  1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2015. EE. UU.: Department of Health and Human Services; 2016.

  2. Centers for Disease Control and Prevention. CDC Fact Sheet. Reported STDs in the United States 2015 National Data for Chlamydia, Gonorrhea, and Syphilis. EE. UU.: Department of Health and Human Services; 2016.

  3. World Health Organization. Report on global sexually transmitted infection surveillance 2015. Ginebra, Suiza: World Health Organization; 2016.

  4. World Health Organization. WHO Guidelines for the Treatment of Chlamydia trachomatis. Ginebra, Suiza: World Health Organization; 2016.

  5. Lane AB Decker CF. Chlamydia trachomatis infections. Dis Mon. 2016;62:269-273.

  6. Ahmadi A, Khodabandehloo M, Ramazanzadeh R, Farhadifar F, Roshani D, Ghaderi E, et al. The relationship between Chlamydia trachomatis genital infection and spontaneous abortion. J Reprod Infertil. 2016;17:110‑116.

  7. Meyer T. Diagnostic procedures to detect chlamydia trachomatis infections. Microorganisms. 2016;4:25.

  8. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.

  9. Bakheit A, Al-Hadiya B, Abd-Elgalil A. Azithromycin. En: Brittain H. Profiles of drug substances, excipients and related methodology. EE. UU.: Academic Press; 2014.

  10. Cobos-Trigueros N, Ateka O, Pitart C, Vila J. Macrólidos y cetólidos. Enf Infec Microb Clin. 2009;27:412-418.

  11. Jelić D, Antolović R. From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. Antibiotics (Basel). 2016;5:29.

  12. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29:497-502.

  13. Geisler W, Uniyal A, Lee J, Lensing S, Johnson S, Perry R et al. Azithromycin versus doxycycline for urogenital chlamydia trachomatis infection. New Engl J Med. 2015;373:2512-2521.

  14. Kong FY, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley C, et al. azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59:193-205.

  15. Craig A, Kong FY, Yeruva L, Hocking JS, Rank RG, Wilson DP, et al. Is it time to switch to doxycycline from azithromycin for treating genital chlamydial infections in women? Modelling the impact of autoinoculation from the gastrointestinal tract to the genital tract. BMC Infect Dis. 2015;15:200.

  16. Kong FY, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:1290-1297.

  17. Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun. 2014;82:1362-1371.

  18. Heiligenberg M, Lutter R, Pajkrt D, Adams K, De-Vries H, Heijman T, et al. Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men. Clin Vaccine Immunol. 2013;20:1517-1523.

  19. Gratrix J, Brandley J, Dane M, Plitt S, Smyczek P, Read R, et al. A retrospective review of treatment failures using azithromycin and doxycycline in the treatment of rectal chlamydia infections in women and men who have sex with Men. Sex Transm Dis. 2016;43:110-112.

  20. Khosropour CM, Dombrowski JC, Barbee LA, Manhart L, Golden MR. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis. 2014;41:79-85.

  21. Horner PJ. Azithromycin antimicrobial resistance and genital chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect. 2012;88(3):154-156.

  22. Ziklo N, Huston W, Hocking J, Timms P. Chlamydia trachomatis genital tract infections: when host immune response and the microbiome collide. Trends Microbiol. 2016;24:750-765.

  23. Cossé MM, Hayward RD, Subtil A. One face of chlamydia trachomatis: the infectious elementary body. Curr Top Microbiol Immunol. 2018;412:35‑58.

  24. Elgalib A, Alexander S, Tong C, White JA. Seven days of doxycycline is an effective treatment for asymptomatic rectal chlamydia trachomatis infection. Int J STD AIDS. 2011;22:474-477.

  25. Kong FY, Hocking JS. Treatment challenges for urogenital and anorectal chlamydia trachomatis. BMC Infect Dis. 2015;15:293.

  26. Madhivanan P, Krupp K. Antibiotic resistance in prevalent bacterial and protozoan sexually transmitted infections. Indian J Sex Transm Dis AIDS. 2015;36:3.

  27. Wind C, Schim Van Der Loeff MF, Unemo M, Schuurman R, Van-Dam AP, De-Vries H. Time to clearance of chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae: a prospective cohort study. BMC Infect Dis. 2016;16:554.

  28. Dukers-Muijrers N, Morré SA, Speksnijder A, Van Der Sande M, Hoebe C. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One. 2012;7(3):e34108.

  29. Lazenby GB, Korte JE, Tillman S, Brown FK, Soper DE. A recommendation for timing of repeat chlamydia trachomatis test following infection and treatment in pregnant and nonpregnant women. Int J STD AIDS. 2016;28:902-909.



>Revistas >Gaceta Médica de México >Año2018, No. 6
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019